AbCellera Biologics Inc. (ABCL) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $3.4B · $11.28 · 52-week range $2.75–$12.58

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-08-24	Hayden Michael R	director	53,613	$10.64	$570,442	SEC Form 4
2026-08-18	Montalbano John S.	director	10,000	$11.03	$110,300	SEC Form 4
2026-08-14	Booth Andrew	officer: Chief Financial Officer	37,200	$10.32	$383,904	SEC Form 4
2026-08-12	Hayden Michael R	director	46,387	$10.37	$481,033	SEC Form 4
2026-05-14	Montalbano John S.	director	20,000	$4.77	$95,400	SEC Form 4

Financial health

Altman Z-Score 5.09 · Piotroski F-Score 3/9 · Cash $534M · Debt $143M

ClearOcean signal read

ClearOcean's model currently scores ABCL as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — ABCL Form 4
How ClearOcean reads insider activity

Last updated September 02, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.